Mural Oncology plc (NASDAQ : MURA ) Stock

MWN-AI** Summary

MWN-AI** Analysis

**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.

Description

Mural Oncology¿s pipeline is built to address difficult-to-treat tumor types where checkpoint inhibitors are not effective. The Company¿s lead product candidate, nemvaleukin alfa (nemvaleukin), is an investigational, engineered interleukin-2 (IL-2) cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 (rhIL-2), while mitigating the hallmark toxicities of native IL-2 in difficult-to-treat cancers with high unmet need. Nemvaleukin is currently in two potentially registrational studies: one for the treatment of mucosal melanoma as a monotherapy and one for the treatment of platinum-resistant ovarian cancer (PROC) in combination with pembrolizumab.

Quote

Last:	$2.04
Change Percent:	-1.92%
Open:	$2.03
Close:	$2.08
High:	$2.04
Low:	$2.03
Volume:	54,698
Last Trade Date Time:	12/04/2025 12:30:29 pm

Stock Data

Market Cap:	$35,382,751
Float:	12,698,755
Insiders Ownership:	N/A
Institutions:	59
Short Percent:	N/A
Industry:	Biotechnology & Life Sciences
Sector:	Healthcare
Website:
Country:	IE
City:	Dublin 2